Seaport Therapeutics (NASDAQ:SPTX – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research report issued to clients and investors on Thursday, Benzinga reports. They currently have a $50.00 target price on the stock. HC Wainwright’s target price indicates a potential upside of 129.89% from the stock’s […]

Opus Genetics (NASDAQ:IRD – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a note issued to investors on Wednesday, Benzinga reports. They currently have a $8.00 price target on the stock. HC Wainwright’s target price suggests a potential upside of 46.65% from the company’s previous close. […]

Intellia Therapeutics (NASDAQ:NTLA – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a note issued to investors on Wednesday, Benzinga reports. They currently have a $25.00 target price on the stock. HC Wainwright’s target price indicates a potential upside of 96.23% from the stock’s current price. A […]

Protalix BioTherapeutics (NYSE:PLX – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research note issued to investors on Wednesday, Benzinga reports. They presently have a $12.00 target price on the stock. HC Wainwright’s target price suggests a potential upside of 360.65% from the company’s current price. […]

Adlai Nortye (NASDAQ:ANL – Get Free Report)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They presently have a $20.00 target price on the stock. HC Wainwright’s price target would indicate a potential upside of 28.04% from the company’s current price. […]

Brainsway (NASDAQ:BWAY – Get Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued to clients and investors on Tuesday, Benzinga reports. They currently have a $19.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 32.36% from the stock’s previous close. A […]

NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They currently have a $52.00 price target on the stock. HC Wainwright’s price objective would suggest a potential upside of 104.72% from the stock’s previous close. Other […]

Bit Digital (NASDAQ:BTBT – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They presently have a $4.00 price target on the stock. HC Wainwright’s target price suggests a potential upside of 143.90% from the stock’s current price. Other […]

WhiteFiber (NASDAQ:WYFI – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research note issued on Thursday, Benzinga reports. They currently have a $37.00 price objective on the stock. HC Wainwright’s price target would indicate a potential upside of 113.75% from the company’s current price. Several other equities […]

Oruka Therapeutics (NASDAQ:ORKA – Get Free Report)‘s stock had its “buy” rating reiterated by HC Wainwright in a research report issued on Thursday, Benzinga reports. They presently have a $120.00 target price on the stock. HC Wainwright’s target price would suggest a potential upside of 30.96% from the company’s current price. Other research analysts have […]

BridgeBio Pharma (NASDAQ:BBIO – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research report issued on Wednesday, Benzinga reports. They presently have a $120.00 price target on the stock. HC Wainwright’s price objective would suggest a potential upside of 56.72% from the stock’s previous close. Other […]

Cytokinetics (NASDAQ:CYTK – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They presently have a $140.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s target price indicates a potential upside of 94.20% from the stock’s previous close. […]